Celldex Therapeutics (CLDX) Enterprise Value (2010 - 2026)

Celldex Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$451.5 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 32.95% year-over-year to -$451.5 million; the TTM figure through Mar 2026 stood at -$451.5 million (up 32.95% YoY), while the FY2025 annual figure was -$518.6 million, up 28.5% from the prior year.
• Enterprise Value was -$451.5 million for Q1 2026 at Celldex Therapeutics, up from -$518.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$235.3 million in Q3 2023 to a low of -$823.8 million in Q1 2024.
• Historically, Enterprise Value has averaged -$501.2 million across 5 years, with a median of -$451.5 million in 2026.
• The sharpest annual moves came in 2024 and 2026: Enterprise Value sank 221.23% in 2024, then surged 32.95% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$305.0 million in 2022, then tumbled by 38.91% to -$423.6 million in 2023, then slumped by 71.22% to -$725.3 million in 2024, then gained by 28.5% to -$518.6 million in 2025, then advanced by 12.94% to -$451.5 million in 2026.
• The last three Enterprise Value figures came in at -$451.5 million (Q1 2026), -$518.6 million (Q4 2025), and -$583.2 million (Q3 2025), per Business Quant data.